Evidence map›Paper›PMID 41239082›Full record

ArticleOncology and therapy2026

Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.

Sarah Sammons, Denise A Yardley, Priyanka Sharma, Vijayakrishna K Gadi, Mark Pegram, Purnima Pathak, Huilin Hu, Gary Sopher, Peter A Fasching

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah SammonsDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. sarahl_sammons@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-2589-9422
Denise A YardleyDepartment of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.
Priyanka SharmaDepartment of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA.
Vijayakrishna K GadiDivision of Hematology and Oncology, University of Illinois Cancer Center, Chicago, IL, USA.
Mark PegramStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Purnima PathakNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Huilin HuNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Gary SopherNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Peter A FaschingGynecology and Obstetrics Translational Medicine, University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CDK4/6 inhibitorsHR+/HER2− metastatic breast cancerReal-world evidence

Identifiers

PMID41239082
PMCPMC12992867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.